Journal: Drug Delivery
Article Title: Lipid nanoparticles with aptamers enable targeted mRNA delivery to CD4⁺ T cells
doi: 10.1080/10717544.2026.2637266
Figure Lengend Snippet: (A) eGFP expression in SUP-T1 (CD4⁺) and HSB2 (CD4⁻) cells following treatment with mRNA-loaded LNPs formulated with MC3 or SM102, either non-targeting, Apt62-modified (25:1 or 100:1), or anti-human CD4 mAb-conjugated. (B) Representative flow cytometry histograms showing eGFP signal in live, singlet-gated in SUP-T1 (CD4⁺) and HSB2 (CD4⁻) cells that were untreated (non-transfected) or treated with SM102-Apt62:100 or SM102 anti-human CD4 mAb-modified LNPs. (C) Quantification of mean fluorescence intensity (MFI) of SUP-T1 (CD4⁺) and HSB2 (CD4⁻) populations corresponding to panel (B). Data represent mean±SD ( n = 4). Statistical significance was determined using two-way ANOVA followed by Tukey's multiple comparisons test; **** p < 0.0001, *** p < 0.001, ** p < 0.01, ####p < 0.0001 versus corresponding CD4⁺ population.
Article Snippet: CD4 + SUPT-1 (Cat. No. CRL-1942) and CD4 - HSB-2 (Cat. No. CCL-120.1) human cell lines, Roswell Park Memorial Institute medium (RPMI-1640, Cat. No. 30-2001), and Iscove's modified Dulbecco's medium (IMDM, Cat. No. 30-2005) culture media were obtained from the American Type Culture Collection (Virginia, USA).
Techniques: Expressing, Modification, Flow Cytometry, Transfection, Fluorescence